Alpine Immune Sciences (NASDAQ:ALPN) Stock Price Down 5.6%

Alpine Immune Sciences, Inc. (NASDAQ:ALPNGet Free Report)’s stock price traded down 5.6% during trading on Wednesday . The company traded as low as $36.80 and last traded at $37.02. 583,722 shares changed hands during mid-day trading, a decline of 48% from the average session volume of 1,126,938 shares. The stock had previously closed at $39.21.

Analysts Set New Price Targets

ALPN has been the topic of a number of recent analyst reports. HC Wainwright increased their price objective on shares of Alpine Immune Sciences from $32.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, March 19th. Wedbush restated an “outperform” rating and issued a $47.00 target price on shares of Alpine Immune Sciences in a research note on Tuesday, March 19th. Morgan Stanley boosted their price target on Alpine Immune Sciences from $30.00 to $47.00 and gave the company an “overweight” rating in a report on Tuesday, March 19th. Wolfe Research initiated coverage on Alpine Immune Sciences in a report on Thursday, February 15th. They issued an “outperform” rating and a $44.00 price target for the company. Finally, Oppenheimer reissued an “outperform” rating and issued a $44.00 price target (up from $33.00) on shares of Alpine Immune Sciences in a report on Tuesday, March 19th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $38.86.

Check Out Our Latest Stock Analysis on Alpine Immune Sciences

Alpine Immune Sciences Stock Performance

The company has a 50 day moving average of $33.18 and a 200-day moving average of $21.24. The stock has a market cap of $2.50 billion, a price-to-earnings ratio of -61.27 and a beta of 1.14.

Institutional Investors Weigh In On Alpine Immune Sciences

A number of hedge funds have recently bought and sold shares of the stock. HighPoint Advisor Group LLC acquired a new stake in Alpine Immune Sciences in the 4th quarter valued at about $290,000. Vanguard Group Inc. boosted its stake in shares of Alpine Immune Sciences by 51.5% in the fourth quarter. Vanguard Group Inc. now owns 2,234,767 shares of the biotechnology company’s stock valued at $42,595,000 after buying an additional 759,888 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Alpine Immune Sciences by 176.6% in the fourth quarter. Wellington Management Group LLP now owns 109,882 shares of the biotechnology company’s stock valued at $2,094,000 after buying an additional 70,151 shares in the last quarter. American International Group Inc. raised its holdings in Alpine Immune Sciences by 2.2% during the fourth quarter. American International Group Inc. now owns 16,185 shares of the biotechnology company’s stock worth $308,000 after purchasing an additional 343 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Alpine Immune Sciences by 20.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,687,278 shares of the biotechnology company’s stock worth $32,161,000 after purchasing an additional 290,834 shares during the last quarter. Institutional investors and hedge funds own 75.17% of the company’s stock.

Alpine Immune Sciences Company Profile

(Get Free Report)

Alpine Immune Sciences, Inc operates as a clinical-stage immunotherapy company. It focuses on creating various immunotherapies through protein engineering technologies for autoimmune and inflammatory diseases. The company has strategic collaborations with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development.

Recommended Stories

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.